La vendita allo scoperto per Investcorp Credit dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Investcorp Credit. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Investcorp Credit (NASDAQ:ICMB) Azioni, Report sulle vendite allo scoperto

Investcorp Credit

Investcorp Credit Management BDC Inc is an externally managed, non-diversified closed-end management investment firm that has elected to be regulated as a business development company (BDC). Its investment objective is to maximize total return to stockholders in the form of current income and capital appreciation by investing in debt and related equity of privately held lower middle-market companies. The company principally invests in the debt of middle-market companies, which it defines as those companies that have an enterprise value.

Investcorp Credit Management BDC, Inc. - Common Stock

Investcorp Credit Management BDC Inc

Trading Ideas

BAOS

Baosheng Media Group Shares Resume Trade

WBUY

Webuy Global Shares Resume Trade

Needham analyst Ryan MacDonald reiterates Chegg (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHGG#NYSE">CHGG</a>) from Hold to Hold.

News

Reiteration

Analyst Ratings

CHGG

Needham Reiterates Hold on Cheggto Hold

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Actinium Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ATNM#AMEX">ATNM</a>) with a Buy and maintains $4 price target.

Price Target

ATNM

HC Wainwright & Co. Reiterates Buy on Actinium Pharma, Maintains $4 Price Target

Baosheng Media Group Shares Halted On Circuit Breaker To The Upside, Stock Now Up 68.8%

U.S. stocks traded higher midway through trading, with the Dow Jones index gaining around 900 points on Monday.
The Dow traded up 2.20% to 42,155.11 while the NASDAQ gained 3.59% to 18,572.58. The S&amp;P 500 also rose, gaining, 2.59% to 5,806.23.
Check This Out: <a href="https://www.benzinga.com/analyst-ratings/price-target/25/05/45342900/5-stock-picks-last-week-from-wall-streets-most-accurate-analysts-5">5 Stock Picks Last Week From Wall Street&#8217;s Most Accurate Analysts</a>
Leading and Lagging Sectors Consumer discretionary shares jumped by 4.8% on Monday.
In trading on Monday, consumer staples stocks fell by 0.4%.
Top Headline
NRG Energy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRG#NYSE">NRG</a>) reported better-than-expected first-quarter financial results.
NRG Energy posted adjusted earnings of $2.62 per share, beating market estimates of $1.49 per share. The company's quarterly sales came in at $8.59 billion versus expectations of $7.83 billion.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul class="wp-block-list">
<li>Gryphon Digital Mining, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRYP#NASDAQ">GRYP</a>) shares shot up 274% to $1.9450 after the company announced a merger agreement with American Bitcoin.</li>
<li>Shares of Kindly MD, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KDLY#NASDAQ">KDLY</a>) got a boost, surging 407% to $19.77 after the company announced a merger agreement with Nakamoto Holdings to start a Bitcoin treasury strategy.</li>
<li>NRG Energy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRG#NYSE">NRG</a>) shares were also up, gaining 22% to $145.08 after the company reported better-than-expected first-quarter financial results.</li>
</ul>
Equities Trading DOWN
<ul class="wp-block-list">
<li>Superior Industries International, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUP#NYSE">SUP</a>) shares dropped 69% to $0.8950 after the company reported worse-than-expected first-quarter EPS results and announced it is withdrawing its FY25 guidance.</li>
<li>Shares of Orla Mining Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORLA#NYSE">ORLA</a>) were down 16% to $9.27 after the company reported worse-than-expected first-quarter sales results.</li>
<li>Pan American Silver Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAAS#NYSE">PAAS</a>) was down, falling 14% to $23.30 after the company announced it entered into an agreement to acquire all of the issued and outstanding common shares of MAG Silver.</li>
</ul>
Commodities In commodity news, oil traded up 3.2% to $62.96 while gold traded down 2.9% at $3,247.10.
Silver traded down 0.2% to $32.84 on Monday, while copper fell 0.8% to $4.6175.
Euro zone
European shares were higher today. The eurozone's STOXX 600 gained 0.89%, while Spain's IBEX 35 Index rose 0.28%. London's FTSE 100 gained 0.35%, Germany's DAX 40 gained 0.02% and France's CAC 40 gained 1.18% during the session.
Asia Pacific Markets
Asian markets closed higher on Monday, with Japan's Nikkei gaining 0.38%, Hong Kong's Hang Seng Index gaining 2.98%, China's Shanghai Composite Index gaining 0.82% and India's BSE Sensex jumping 3.74%.
Economics
The U.S. government budget report for April will be released today.
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45347296/this-target-analyst-turns-bearish-here-are-top-5-downgrades-for-monday">This Target Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday</a> </li>
</ul>
Photo via Shutterstock

Earnings

Equities

Eurozone

Commodities

Intraday Update

Markets

GRYP

KDLY

ORLA

PAAS

Dow Jumps 900 Points; KindlyMD Shares Spike Higher

Webuy Global Shares Halted On Circuit Breaker To The Downside, Stock Now Down -31.4%

RBC Capital analyst Daniel Perlin maintains TaskUs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TASK#NASDAQ">TASK</a>) with a Sector Perform and lowers the price target from $20 to $16.5.

TASK

RBC Capital Maintains Sector Perform on TaskUs, Lowers Price Target to $16.5

RBC Capital analyst Matthew McKellar maintains Sylvamo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLVM#NYSE">SLVM</a>) with a Sector Perform and lowers the price target from $70 to $61.

SLVM

RBC Capital Maintains Sector Perform on Sylvamo, Lowers Price Target to $61

Spectral AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDAI#NASDAQ">MDAI</a>) is gearing up to announce its quarterly earnings on Tuesday, 2025-05-13. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Spectral AI will report an earnings per share (EPS) of $-0.15.
The market awaits Spectral AI's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Earnings History Snapshot</h3>
The company's EPS missed by $0.27 in the last quarter, leading to a 11.72% drop in the share price on the following day.

<img src="https://www.benzinga.com/files/images/story/2025/1747066029_0.png" alt="eps graph" />
<h3>Tracking Spectral AI's Stock Performance</h3>
Shares of Spectral AI were trading at $1.24 as of May 09. Over the last 52-week period, shares are down 22.78%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/MDAI/earnings">To track all earnings releases for Spectral AI visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MDAI

What's Next: Spectral AI's Earnings Preview

RBC Capital analyst Darko Mihelic maintains Sun Life Financial (TSX:<a class="ticker" href="https://www.benzinga.com/stock/SLF#TSX">SLF</a>) with a Outperform and raises the price target from C$82 to C$88.

TSX:SLF

RBC Capital Maintains Outperform on Sun Life Financial, Raises Price Target to C$88

Lineage Cell Therapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/LCTX#AMEX">LCTX</a>) will release its quarterly earnings report on Tuesday, 2025-05-13. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Lineage Cell Therapeutics to report an earnings per share (EPS) of $-0.03.
Anticipation surrounds Lineage Cell Therapeutics's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Historical Earnings Performance</h3>
In the previous earnings release, the company beat EPS by $0.01, leading to a 0.36% increase in the share price the following trading session.
Here's a look at Lineage Cell Therapeutics's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.03</td>
<td>-0.03</td>
<td>-0.04</td>
<td>-0.04</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.02</td>
<td>-0.02</td>
<td>-0.03</td>
<td>-0.04</td>
</tr>
<tr>
<td>Price Change %</td>
<td>0.0%</td>
<td>-2.0%</td>
<td>3.0%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1747065929_0_0.png" alt="eps graph" />
<h3>Tracking Lineage Cell Therapeutics's Stock Performance</h3>
Shares of Lineage Cell Therapeutics were trading at $0.44 as of May 09. Over the last 52-week period, shares are down 55.36%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<h3>Analyst Opinions on Lineage Cell Therapeutics</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Lineage Cell Therapeutics.
Analysts have provided Lineage Cell Therapeutics with 5 ratings, resulting in a consensus rating of Buy. The average one-year price target stands at $5.0, suggesting a potential 1036.36% upside.
<h3>Analyzing Analyst Ratings Among Peers</h3>
In this comparison, we explore the analyst ratings and average 1-year price targets of and Macrogenics, three prominent industry players, offering insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Neutral trajectory for Macrogenics, with an average 1-year price target of $2.0, suggesting a potential 354.55% upside.</li>
</ul>
<h3>Peer Metrics Summary</h3>
The peer analysis summary provides a snapshot of key metrics for and Macrogenics, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lineage Cell Therapeutics</td>
<td>Buy</td>
<td>37.36%</td>
<td>$2.71M</td>
<td>-4.53%</td>
</tr>
<tr>
<td>Macrogenics</td>
<td>Neutral</td>
<td>93.47%</td>
<td>$12.24M</td>
<td>-13.06%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Lineage Cell Therapeutics ranks higher than its peers in Revenue Growth and Gross Profit, indicating strong performance in these areas. However, it lags behind in Return on Equity. Overall, Lineage Cell Therapeutics is positioned in the middle compared to its peers based on the provided metrics.
<h3>Discovering Lineage Cell Therapeutics: A Closer Look</h3>
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
<h3>Financial Insights: Lineage Cell Therapeutics</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Lineage Cell Therapeutics's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 37.36%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Lineage Cell Therapeutics's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -114.12%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Lineage Cell Therapeutics's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -4.53% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Lineage Cell Therapeutics's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -3.12% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Lineage Cell Therapeutics's debt-to-equity ratio is below the industry average. With a ratio of 0.03, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<a href="https://www.benzinga.com/quote/LCTX/earnings">To track all earnings releases for Lineage Cell Therapeutics visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

LCTX

Examining the Future: Lineage Cell Therapeutics's Earnings Outlook

WIIM

RMTI

RMTI stock has given up its prior gain. Rockwell Medical shares were trading higher after the company reported better-than-expected Q1 financial results.

RBC Capital analyst Darko Mihelic maintains Sun Life Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLF#NYSE">SLF</a>) with a Outperform and raises the price target from $82 to $88.

RBC Capital Maintains Outperform on Sun Life Financial, Raises Price Target to $88

The Consumer Price Index for April, due Tuesday morning, could test Wall Street's renewed bullishness after a major U.S.-China tariff rollback<a href="https://www.benzinga.com/government/regulations/25/05/45347089/wall-street-rips-higher-as-tariff-truce-halts-us-china-economic-escalation"> fueled risk-on sentiment. </a>
Despite a slightly defused trade war, the inflation print could tighten the Fed's hand further, especially if prices came in hotter than forecast.
Wall Street economists agree that the annual headline inflation rate will remain at 2.4%—the 49th straight month above the Federal Reserve's 2% target.
Inflation is forecast to rebound from a 0.1% drop in March to 0.3% in April. Core CPI, which excludes food and energy, is expected to rise 0.3% monthly and hold steady at 2.8% annually.
Bank America&#8217;s economist Stephen Juneau warns that "larger increases are in the pipeline" due to front-loaded demand and the lingering impact of April's tariff shock.
See Also: <a href="https://www.benzinga.com/news/earnings/earnings-misses/25/05/45353447/amc-networks-sales-drop-as-analyst-warns-of-continued-pressure-on-revenue">AMC Networks&#8217; Sales Drop As Analyst Warns Of &#8216;Continued Pressure&#8217; On Revenue</a>
<h3 class="wp-block-heading">Fed Rate Cut Expectations Collapse After US-China Trade Truce</h3>
The surprise U.S.-China trade breakthrough on Monday delivered another blow to short-term Fed cut bets. With tariffs slashed by over 100 percentage points for at least 90 days, economic uncertainty tied to supply chains and pricing has decreased. 
Markets now price just an 8% probability of a 25-basis-point cut in June, according to CME FedWatch data. That's down from nearly 40% a week ago. The odds for a July cut stand at 42%, while expectations for two cuts by December have dropped to 72%, from nearly three cuts priced before last week's FOMC meeting.
The Federal Reserve kept rates unchanged for a third consecutive meeting in May and emphasized that "uncertainty about the economic outlook has increased," citing risks of both higher unemployment and persistent inflation. 
Fed Chair Jerome Powell said policy is in a "good place" and the central bank will wait for more clarity on trade and prices.
 "Inflation remains above the Federal Open Market Committee's 2% target, and further progress on disinflation has been slow," said Fed Governor Adriana Kugler on Monday, reinforcing the central bank's cautious stance.
<h3 class="wp-block-heading">Tariffs: A Short-Term Boost To Prices?</h3>
While the U.S.-China truce reduces long-term inflation risk, at least from a supply-side perspective, April may still show upward price pressures as businesses and consumers reacted to the previous tariff escalation. 
Bank of America indicates that tariff revenues and effective rates rose about 2 percentage points in April — a modest but broad-based input cost pressure.
Core goods inflation is expected to rise 0.1% month-over-month after a 0.1% drop in March, driven by front-loaded demand and rising auto prices. Juneau highlighted a 2.7% monthly spike in the Manheim Used Vehicle Value Index as another red flag.
"Tariffs should be a modest boost to goods prices this month," Juneau said, "but larger increases are in the pipeline."
Services inflation may be tamer. The analyst expects a slight moderation in rent inflation and is watching categories like airfares, lodging and car rentals for signs of weakening demand, which is already visible in card spending data.
According to veteran Wall Street investor Ed Yardeni, &#8220;increases like the 2.7% month-over-month jump in the Manheim Used Vehicle Value Index in April from March bear watching.&#8221;
&#8220;Higher prices paid for imports due to tariffs are also driving up service sector firms' costs, feeding through to higher prices, notably in consumer-facing industries such as restaurants and hotels,&#8221; said S&amp;P Global&#8217;s chief economist Chris Williamson in the latest U.S. Services PMI report.
<h3 class="wp-block-heading">What To Expect In Markets</h3>
It's unlikely Tuesday's inflation report derails Wall Street&#8217;s tariff-relief rally—unless the numbers come in well above expectations. 
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) — which tracks the S&amp;P 500 index — surged 2.6% on Monday to an over two-month high on hopes that the trade truce reduces supply-side price pressures and stabilizes global growth.
Still, sticky inflation would signal that the Fed's 2% goal remains distant, reinforcing its higher-for-longer interest rate stance. A hotter April inflation print might strengthen the dollar and increase bond yields.
The U.S. dollar, which weakened during April's tariff escalation, is <a href="https://www.bloomberg.com/quote/BBDXY:IND?sref=TBDibEcD">rebounding</a> as of May 12. Meanwhile, Treasury yields are climbing: the 30-year bond yield hovered at 4.87% on Monday, near its 2025 high of 5%.
Now Read: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/health-care/25/05/45339399/trump-says-prescription-drug-prices-set-to-drop-by-30-to-80-almost-immediately-thanks-to-most-favored-nation-plan-mark-cuban-urges-president-to-force-tran">Trump Says Prescription Drug Prices Set To Drop By 30% To 80% &#8216;Almost Immediately,&#8217; Mark Cuban Urges President To &#8216;Force Transparency&#8217;</a><span class="author" style="box-sizing: border-box; border: 0px solid rgb(229, 231, 235); --tw-scale-x: 1; --tw-scale-y: 1; --tw-pan-x: ; --tw-pan-y: ; --tw-pinch-zoom: ; --tw-scroll-snap-strictness: proximity; --tw-gradient-from-position: ; --tw-gradient-via-position: ; --tw-gradient-to-position: ; --tw-ordinal: ; --tw-slashed-zero: ; --tw-numeric-figure: ; --tw-numeric-spacing: ; --tw-numeric-fraction: ; --tw-ring-inset: ; --tw-ring-offset-width: 0px; --tw-ring-offset-color: #fff; --tw-ring-color: rgba(59,130,246,.5); --tw-ring-offset-shadow: 0 0 #0000; --tw-ring-shadow: 0 0 #0000; --tw-shadow: 0 0 #0000; --tw-shadow-colored: 0 0 #0000; --tw-blur: ; --tw-brightness: ; --tw-contrast: ; --tw-grayscale: ; --tw-hue-rotate: ; --tw-invert: ; --tw-saturate: ; --tw-sepia: ; --tw-drop-shadow: ; --tw-backdrop-blur: ; --tw-backdrop-brightness: ; --tw-backdrop-contrast: ; --tw-backdrop-grayscale: ; --tw-backdrop-hue-rotate: ; --tw-backdrop-invert: ; --tw-backdrop-opacity: ; --tw-backdrop-saturate: ; --tw-backdrop-sepia: ; --tw-contain-size: ; --tw-contain-layout: ; --tw-contain-paint: ; --tw-contain-style: ;"></li>
</ul>
Image: Shutterstock

Analyst Color

Macro Economic Events

Broad U.S. Equity ETFs

Econ #s

Economics

Federal Reserve

ETFs

New Inflation Data Hits Tuesday: Why It Could Kill Fed Rate Cut Hopes

RBC Capital analyst Daniel Perlin maintains Rackspace Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXT#NASDAQ">RXT</a>) with a Sector Perform and lowers the price target from $3 to $2.

RBC Capital Maintains Sector Perform on Rackspace Technology, Lowers Price Target to $2

Molina Healthcare's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) short percent of float has fallen 26.75% since its last report. The company recently reported that it has 954 thousand shares sold short, which is 2.3% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.0 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Molina Healthcare Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747065633_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Molina Healthcare has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Molina Healthcare's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Molina Healthcare's peer group average for short interest as a percentage of float is 4.68%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Is Molina Healthcare Gaining or Losing Market Support?

In the current session, the stock is trading at $34.93, after a 4.75% spike. Over the past month, Lincoln National Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LNC#NYSE">LNC</a>) stock increased by 15.52%, and in the past year, by 17.42%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2025/1747065630_0.png" alt="Past Year Chart" />

<h3>Lincoln National P/E Ratio Analysis in Relation to Industry Peers</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Lincoln National has a lower P/E than the aggregate P/E of 14.87 of the Insurance industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1747065631_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Price Over Earnings Overview: Lincoln National

Churchill Downs's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHDN#NYSE">CHDN</a>) short percent of float has fallen 4.17% since its last report. The company recently reported that it has 1.67 million shares sold short, which is 2.76% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.22 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Churchill Downs Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747065628_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Churchill Downs has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Churchill Downs's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Churchill Downs's peer group average for short interest as a percentage of float is 5.40%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

CHDN

How Is The Market Feeling About Churchill Downs?

Reliance (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RS#NYSE">RS</a>) has outperformed the market over the past 20 years by 6.36% on an annualized basis producing an average annual return of 14.57%. Currently, Reliance has a market capitalization of $15.67 billion. 
Buying $1000 In RS: If an investor had bought $1000 of RS stock 20 years ago, it would be worth $15,094.99 today based on a price of $296.32 for RS at the time of writing.
<h3>Reliance's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747065625_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comments

Investcorp Credit

Vendite allo scoperto

Investcorp Credit (NASDAQ:ICMB) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO